Tom joined the Austin office as an associate August 2013. His practice focuses on helping clients both acquire patents and resolve patent disputes. He has research experience in several fields of biology, with a primary focus in cell biology, molecular biology, and genetics.
Tom assists clients resolve patent disputes in both district court litigation and post-grant validity challenges before the United States Patent & Trademark Office. Tom has drafted several petitions for inter partes review, participated in inter partes review trials, worked with technical experts to prepare opinions regarding patent validity, drafted claim construction and other briefs in district court litigation, prepared invalidity contentions, and done a variety of legal research and persuasive writing to advocate for clients.
Tom drafts and prosecutes patent applications in a variety of technical areas, including in the biotechnology, bioinformatics, pharmaceutical, chemistry, and energy fields. Tom also assists clients in formulating patent strategies to protect their valuable innovations.
Tom has done a variety of other IP-related work, including evaluating patent portfolios for due diligence reviews, drafting invalidity and noninfringement opinions, and advising clients regarding patent marking, internet domain name monitoring, and a variety of other legal issues.
Tom got the highest score on the July 2013 Texas Bar Exam.
JD, summa cum laude, BYU - J. Reuben Clark Law School, 2013
Ph.D, Biology, Johns Hopkins University, 2010
BS, Microbiology, Brigham Young University, 2002
Tom is registered to practice before the United States Patent & Trademark Office.
- Texas State Bar
- US Patent & Trademark Attorney
- Co-author, CH. 10, "Recent Developments in Inter Partes Review Proceedings," 29th Annual Advanced Intellectual Property Law Course, State Bar of Texas, Feb. 2016.
Memberships and activities
Tom serves pro bono as an attorney ad litem for a foster child and is an Assistant Scoutmaster with the Boy Scouts.
Norton Rose Fulbright advised Shionogi & Co. and Purdue Pharma L.P. in an alliance for the joint US launch and commercialization of Symproic®..
December 21, 2016